Abstract:BACKGROUND & OBJECTIVE:The manifestations of old acute myelogenous (AML) patients have their special biological and clinical characteristics, with lower response rate to therapy and shorter survival time. This study was to investigate the prognostic factors of elderly patients with AML retrospectively. METHODS:77 patients aged> or =60 years with AML from 1994 to 2005 were admitted to our study and all the possible prognostic factors were analyzed with Kaplan-Meier survival analysis. The significant factors were further analyzed by Cox proportional hazard model analysis. RESULTS:Seventy-two patients were evaluated. The patients aged 60-70 (median survival time was 350 days) had significantly longer survival time than those aged more than 70 (median survival time is 60 days)(P<0.001), which their CR ratios were 71.4% and 29.4% (P=0.001). The patients with performance status 0 or 1 (median survival time was 402 days) had significantly longer survival time than those with performance status 2, 3 or 4 (median survival time was 31 days)(P<0.001), which their CR ratios were 75% and 15% (P<0.001). The patients with primary AML (median survival time was 98 days) had significantly longer survival time than those with secondary AML (median survival time was 32 days)(P=0.007), which their CR ratios were 50% and 0% (P=0.023). The patients treated with sub-standard dosage of anthracycline (median survival time was 293 days) had significantly longer survival time than those treated with reduced dosage of anthracycline (median survival time was 35 days)(P=0.006), which their CR ratios were 63.6% and 33.3% (P=0.02). The patients with bone marrow blast cell ratio< or =50% (median survival time was 98 days ) had significantly longer survival time than those with bone marrow blast cell ratio >50% (median survival time was 55 days)(P=0.006). The patients with favorable karyotype (median survival time was 293 days) had significantly longer survival time than those with unfavorable or normal karyotype (median survival time was 31 days)(P=0.005). The patients without CD34 expression (median survival time was 201 days) had significantly longer survival time than those with CD34 expression(median survival time was 36 days)(P<0.001). The patients with the peripheral blood white blood cell count (PBWBC)>10x10(9)/L (50%) had significantly higher CR ratio than those with PBWBC< or =10x10(9)/L (25%)(P=0.043). The patients received chemotherapy (50%) had significantly higher CR ratio than those received supportive therapy (0%)(P=0.001). In the stepwise COX proportional hazard regression model, all the seven factors related to OS remained independent and significant. CONCLUSIONS:Factors, including age >70, PS 2 to 4, percentage of blasts in bone marrow >50%, secondary AML, unfavorable karyotype, expression of CD34, lower dosage.

Analysis of Clinical Characteristics and Prognostic Factors in Elderly Patients with Acute Myeloid Leukemia

Factors Affecting Early Death and Survival of Patients with Acute Promyelocytic Leukemia Treated with ATRA-Based Therapy Regimens

Efficacy of different remission induction chemotherapy and prognostic analysis in elderly patients with acute myeloid leukemia

Prognostic analysis of non-cytogenetic factors in elderly adults with acute myeloid leukemia]

[Analysis of Age-Specific Cytogenetic Changes among 515 Patients Withacute Myeloid Leukemia].

Aging and Comprehensive Molecular Profiling in Acute Myeloid Leukemia.

Analysis of Characteristics and Clinical Effectiveness of Acute Myeloid Leukemia in the Elderly

Clinical Characterization and Prognostic Factors of 144 Adult Acute Monocytic Leukemia

[Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].

Clinical Features and Prognosis of Elderly Patients with Cytogenetically Normal Acute Myeloid Leukemia

Significance of Clinical Factors As Prognostic Indicators for Mature T-Cell Non-Hodgkin Lymphoma Patients: A Retrospective Analysis of Chinese Cases

[Age-related clinical characteristics and prognosis in non-senile adults with acute myeloid leukemia].

[Analysis of Factors Influencing Overall Survival and Prognosis of AML Patients Over 50 Years Old]

[Clinical Characteristics and Prognosis of 84 Elderly Patients with Acute Myeloid Leukemia].

Acute leukemia in the elderly:clinical analysis of 340 cases

Treatment Patterns and a Prognostic Scoring System for Elderly Acute Myeloid Leukemia Patients: a Retrospective Multicenter Cohort Study in China

Cia_a_343598 55..64

Analysis of Clinical Features and Prognosis in Patients with Refractory/Relapsed Acute Myeloid Leukemia- Results from Our Center

Comparison of efficacy and prognostic factors in elderly acute myelogenous patients with MA or CAG induction chemotherapy regimen

Factors Influencing the Prognosis of Acute Myeloid Leukemia

[Clinical Characteristics and Efficacy Analysis for Patients over 55 Years of Age with Acute Lymphoblastic Leukemia].